144/A: Issuer Information

Name of Issuer

Ascendis Pharma A/S

SEC File Number

001-36815

Address of Issuer

Tuborg Boulevard 12
Hellerup Denmark
DENMARK
DK - 2900

Phone

45-7022-2244

Name of Person for Whose Account the Securities are To Be Sold

Jan Moller Mikkelsen

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Affiliate

144/A: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

ADS

J.P. Morgan Securities LLC
390 Madison Avenue
6th Floor
New York NY 10017

66755

6513952

57152295

09/08/2023

Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

ADS

09/08/2023

Warrant Exercise

Issuer

66755

09/08/2023

Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report

144/A: Remarks and Signature

Remarks

The shares on this filing will be acquired via warrant exercises during month of Sept 2023. Sales represent shares to be sold to cover tax obligations and the payment of the exercise price on warrants exercised, which were due to expire in Q3, 2023.

Date of Notice

09/11/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Jan Mikkelsen

144/A: Filer Information

Submission Contact Information

144/A: Issuer Information

144/A: Securities Information

144/A: Securities To Be Sold

144/A: Securities Sold During The Past 3 Months

144/A: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)